MDM2–309 T>G 基因多態性與東亞人群胃癌風險關系的Meta分析_《中國循證醫學雜志》

作者：

冉恒泉 , 周勇 , 陳博 , 楊平 ,  伍曉汀

四川大學華西醫院胃腸外科（成都 610041）;

關鍵詞：

胃癌鼠雙微體基因2（MDM2）單核苷酸多態性（SNP） Meta分析病例-對照研究

DOI：

10.7507/1672-2531.20130099

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　探討東亞人群中MDM2 SNP309與胃癌風險的關系。
方法　計算機檢索MEDLINE、EMbase和CBM數據庫，檢索時限均為1990.1.1至2012.12.23，搜集研究東亞人群中MDM2 SNP309與胃癌風險的病例-對照研究。由兩位研究者獨立進行文獻篩選、資料提取和納入研究的方法學質量評價后，采用RevMan 5.0軟件進行Meta分析。
結果　共納入5個病例-對照研究，包括1 621例胃癌患者，2 639例對照。Meta分析結果顯示：與野生型純合子（309TT）基因型個體相比，變異純合子（309GG）基因型個體與胃癌風險增高相關［OR=1.54，95%CI（1.04，2.29），P=0.02］，然而雜合子（309TG）基因型個體與胃癌風險增高相關性無統計學意義［OR=1.03，95%CI（0.75，1.42），P=0.006］。在隱形遺傳模式中（GG vs. TG/TT）胃癌風險增高且有統計學意義［OR=1.49，95%CI（1.20，1.84），P=0.07］，但在顯性遺傳模式中（GG/TG vs. TT）這種風險增高無統計學意義［OR=1.18，95%CI（0.84，1.65），P=0.001］。
結論　在東亞人群中，MDM2 309GG基因型個體可能存在較高的胃癌風險。

引用本文： 冉恒泉,周勇,陳博,楊平,伍曉汀. MDM2–309 T>G 基因多態性與東亞人群胃癌風險關系的Meta分析. 中國循證醫學雜志, 2013, 13(5): 560-563. doi: 10.7507/1672-2531.20130099 復制

1.	Ahmedin J, Freddie B, Melissa M, et al. Global cancer statistics. Ca Cancer J Clin, 2011, 61(2): 69-90.
2.	Francesco G, Emma DF, Cornelia MvD, et al. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Current Genomics, 2008, 9(6): 361-374.
3.	Silva F, Carvalho F, Peixoto A, et al. MUC1 gene polymorphism in the gastric carcinogenesis pathway. Eur J Hum Genet, 2001, 9(7): 548- 552.
4.	Correa P, Schneider BG. Etiology of Gastric Cancer: What Is New? Cancer Epidem Biomar, 2005, 14(8): 1865-1868.
5.	Bose I, Ghosh B. The p53-MDM2 network: from oscillations to apoptosis. J Biosci, 2007, 32(5): 991-997.
6.	Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature, 2008, 451(7174): 76-80.
7.	Daujat S, Neel H, Piette J. MDM2: life without p53. Trends in Genetics, 2001, 17(8): 459-464.
8.	Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5): 591-602.
9.	Wan Y, Wu W, Yin Z, et al. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC cancer, 2011, 11(1): 208.
10.	Blok P, Craanen ME, Dekker W, et al. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. J Patho, 1998, 186(1): 36-40.
11.	Well GA, Shea B, O’COnnell D, et al. the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Heath Research Institute.www.ohri. ca/ programs/ clinical_ epidemiology/ oxford asp(accessed Oct 20, 2012).
12.	Cao YY, Zhang XF, Guo W, et al. Association of the MDM2 polymorphisms with susceptibility of esophageal squamous cell carcinoma and that of gastric cardiac adenocarcinoma. Tumor, 2007, 27(8): 628-632.
13.	Wang XY, Yang J, Ho B, et al. Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 2009, 14(5): 114-119.
14.	Yang M, Guo YL, Zhang XM, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 2007, 28(9): 1996-2001.
15.	Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 2006, 24(27): 4434-4440.
16.	Cho YG, Cho BJ, Song JH, et al. No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma, 2008, 55(3): 256-260.
17.	Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res, 2007, 13(14): 4123-4129.
18.	Heidl G, Langhans P, Mellin W, et al. Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma. J Cancer Res Clin Oncol, 1993, 120(1-2): 95-99.
19.	Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA, 2003, 100(3): 776-781.
20.	Gao L, Nieters A, Brenner H. Cell proliferation-related genetic polymorphisms and gastric cancer risk: Systematic review and meta-analysis. Eur J Hum Genet, 2009, 17(12): 1658-1667.

1. Ahmedin J, Freddie B, Melissa M, et al. Global cancer statistics. Ca Cancer J Clin, 2011, 61(2): 69-90.
2. Francesco G, Emma DF, Cornelia MvD, et al. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Current Genomics, 2008, 9(6): 361-374.
3. Silva F, Carvalho F, Peixoto A, et al. MUC1 gene polymorphism in the gastric carcinogenesis pathway. Eur J Hum Genet, 2001, 9(7): 548- 552.
4. Correa P, Schneider BG. Etiology of Gastric Cancer: What Is New? Cancer Epidem Biomar, 2005, 14(8): 1865-1868.
5. Bose I, Ghosh B. The p53-MDM2 network: from oscillations to apoptosis. J Biosci, 2007, 32(5): 991-997.
6. Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature, 2008, 451(7174): 76-80.
7. Daujat S, Neel H, Piette J. MDM2: life without p53. Trends in Genetics, 2001, 17(8): 459-464.
8. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5): 591-602.
9. Wan Y, Wu W, Yin Z, et al. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC cancer, 2011, 11(1): 208.
10. Blok P, Craanen ME, Dekker W, et al. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. J Patho, 1998, 186(1): 36-40.
11. Well GA, Shea B, O’COnnell D, et al. the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Heath Research Institute.www.ohri. ca/ programs/ clinical_ epidemiology/ oxford asp(accessed Oct 20, 2012).
12. Cao YY, Zhang XF, Guo W, et al. Association of the MDM2 polymorphisms with susceptibility of esophageal squamous cell carcinoma and that of gastric cardiac adenocarcinoma. Tumor, 2007, 27(8): 628-632.
13. Wang XY, Yang J, Ho B, et al. Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 2009, 14(5): 114-119.
14. Yang M, Guo YL, Zhang XM, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 2007, 28(9): 1996-2001.
15. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 2006, 24(27): 4434-4440.
16. Cho YG, Cho BJ, Song JH, et al. No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma, 2008, 55(3): 256-260.
17. Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res, 2007, 13(14): 4123-4129.
18. Heidl G, Langhans P, Mellin W, et al. Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma. J Cancer Res Clin Oncol, 1993, 120(1-2): 95-99.
19. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA, 2003, 100(3): 776-781.
20. Gao L, Nieters A, Brenner H. Cell proliferation-related genetic polymorphisms and gastric cancer risk: Systematic review and meta-analysis. Eur J Hum Genet, 2009, 17(12): 1658-1667.

上一篇
血管內皮生長因子與食管癌預后相關性的Meta分析
下一篇
兒童原發性高血壓影響因素的Meta分析

《中國循證醫學雜志》

MDM2–309 T>G 基因多態性與東亞人群胃癌風險關系的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

MDM2–309 T>G 基因多態性與東亞人群胃癌風險關系的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料